There are 3397 resources available
920P - Envafolimab plus chemoradiotherapy for locally advanced nasopharyngeal carcinoma (NPC), a prospective, single-armed phase II trial
Presenter: Xiaohui Wang
Session: Poster session 12
921P - HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer
Presenter: Lisle Nabell
Session: Poster session 12
922P - Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma
Presenter: Glenn Hanna
Session: Poster session 12
923P - Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic head & neck squamous cell carcinoma – subgroup analysis of the PEVOsq basket trial
Presenter: Christophe Le Tourneau
Session: Poster session 12
924P - Polyfunctional HPV16-Specific T cell responses in subjects receiving PDS0101 and pembrolizumab combination treatment for recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC)
Presenter: Kevin Harrington
Session: Poster session 12
925P - Treatment discontinuation of immune checkpoint blockade in patients with head and neck squamous cell carcinoma experiencing complete or nearly complete remission
Presenter: Konrad Klinghammer
Session: Poster session 12
926P - UK national real-world outcome data of first-line pembrolizumab treatment in head and neck squamous cell cancer (HNSCC)
Presenter: Ifigenia Vasiliadou
Session: Poster session 12
927P - Patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab (NIVO) in the first-line (1L) or later-line (2L+) settings in Germany: Updated results from the real-world HANNA study
Presenter: Boris Kubuschok
Session: Poster session 12
928P - Prognostic value of body composition and nutritional assessment in recurrent/metastatic squamous cell carcinoma of head and neck (R/M SCCHN) treated with immunotherapy (IO)
Presenter: Zara Vidales Sepulveda
Session: Poster session 12